Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 3/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7710943 | 0.78 | LAP3 (0.40) | LAP3FDPS | |
| SCHEMBL20001341 | 0.70 | FDPS (0.39) | LAP3FDPSMETAP1ANPEPERAP1 | |
| SCHEMBL7716025 | 0.68 | LAP3 (0.34) | LAP3FDPS | |
| SCHEMBL98484 | 0.66 | LMNA (0.39) | LAP3FDPS | |
| SCHEMBL3305001 | 0.65 | LAP3 (0.34) | LAP3FDPS | |
| SCHEMBL6776493 | 0.65 | LAP3 (0.41) | LAP3FDPSMETAP1ANPEPERAP1 | |
| SCHEMBL11333241 | 0.64 | LAP3 (0.38) | LAP3FDPSMETAP1ANPEPERAP1 | |
| SCHEMBL6633665 | 0.64 | LAP3 (0.34) | LAP3FDPS | |
| Hydrochloric Acid SCHEMBL12494126 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL12494128 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |